Stockscreener 앱 받기
2.20
0.00%
0.00
Acelyrin Inc 주식(SLRN)의 최신 뉴스
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRDG, SLRN, BECN on Behalf of Shareholders - The Malaysian Reserve
ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc.SLRN - MarketScreener
ACELYRIN Optimizes the Sponsor-CRO Data Flow with a Centralized Clinical Data Workbench - Veeva
Alumis and ACELYRIN announce definitive merger plan By Investing.com - Investing.com South Africa
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – OPTN, SLRN, AKYA, SHYF - TradingView
Alumis and ACELYRIN announce definitive merger plan - Investing.com Australia
Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger - The Manila Times
Major Biopharma Merger: Alumis and ACELYRIN Unite with $737M War Chest for Immune Disease Breakthroughs - Stock Titan
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMPS, BECN, SLRN, ALMS on Behalf of Shareholders - The Malaysian Reserve
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDW, BHLB, MHLD, SLRN on Behalf of Shareholders - The Malaysian Reserve
Last-minute suitor nearly upends Alumis, Acelyrin merger - The Business Journals
Indo-Asian News Service - Indo-Asian News Service (IANS)
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – SLRN - Bluefield Daily Telegraph
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – SLRN, TURN, BHLB, MHLD - TradingView
Acelyrin Sees Stock Price Rise Amid Rights Plan - Los Angeles Business Journal
Acelyrin stock plunges after positive Phase II data readout in thyroid eye disease - MSN
TANG CAPITAL MANAGEMENT LLC Increases Stake in Acelyrin Inc - GuruFocus.com
ACELYRIN Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements - The Manila Times
Insider Stock Sales Shake Up ACELYRIN, INC. - TipRanks
Acelyrin’s chief legal officer Murugan Amar sells $10,737 in stock By Investing.com - Investing.com South Africa
Acelyrin CEO Kim Mina sells $49,353 in company stock By Investing.com - Investing.com Canada
Acelyrin chief medical officer Mpofu Shephard sells $8,810 in stock - Investing.com
Acelyrin CEO Kim Mina sells $49,353 in company stock - Investing.com
ACELYRIN Executives Sell Shares to Cover Tax Obligations - TradingView
Acelyrin’s chief legal officer Murugan Amar sells $10,737 in stock - Investing.com India
Acelyrin chief medical officer Mpofu Shephard sells $8,810 in stock By Investing.com - Investing.com Australia
ALUMIS INC. SEC 10-K Report - TradingView
Alumis Inc. Reports Phase 2 and Phase 1 Clinical Data, Announces Merger Agreement with ACELYRIN, and Highlights 2024 Financial Results - Nasdaq
Alumis Doubles R&D Investment, Secures Game-Changing Merger Worth $737M - StockTitan
Acelyrin, Inc. (SLRN): One of the Best Short-Term Stocks to Buy Right Now - Insider Monkey
10 Best Short-Term Stocks to Buy Now with Rebound Potential - Insider Monkey
Makary advances to full senate vote; Acelyrin, Pliant adopt ‘poison pills’ - BioPharma Dive
Pliant Pops Poison Pill as Concentra Threat Looms - BioSpace
Acelyrin adopts rights plan in response to Tang Capital stake By Investing.com - Investing.com Australia
Drug developers Pliant and Acelyrin adopt poison pill provisions to fend off activist investor - The Business Journals
Acelyrin Adopts Poison Pill to Ward Off Tang Capital Buy - BioSpace
Acelyrin stock in focus after poison pill (SLRN:NASDAQ) - Seeking Alpha
Acelyrin Adopts Stockholder Rights Plan; Shares Up Pre-Bell -March 13, 2025 at 08:09 am EDT - Marketscreener.com
Acelyrin adopts rights plan in response to Tang Capital stake - Investing.com India
ACELYRIN Adopts Limited-Duration Stockholder Rights Plan - The Manila Times
Acelyrin: Potential Buyout Led By Concentra Biosciences (NASDAQ:SLRN) - Seeking Alpha
How a skin drug trial could help Peninsula biotech pull off key merger - The Business Journals
Is Acelyrin, Inc. (SLRN) the Best Micro Cap Stock to Buy Now? - Insider Monkey
Acelyrin, Alumis reaffirm strategic, financial rationale of proposed merger - TipRanks
New York State Common Retirement Fund Lowers Position in Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
2.51%
자본화:
|
볼륨(24시간):